Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Analysis of the potential regulatory mechanisms of female and latent genital tuberculosis affecting ovarian reserve function using untargeted metabolomics.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • المؤلفون: Wang Z;Wang Z; Zhang X; Zhang X; Dai B; Dai B; Li D; Li D; Chen X; Chen X
  • المصدر:
    Scientific reports [Sci Rep] 2024 Apr 25; Vol. 14 (1), pp. 9519. Date of Electronic Publication: 2024 Apr 25.
  • نوع النشر :
    Journal Article; Research Support, Non-U.S. Gov't
  • اللغة:
    English
  • معلومة اضافية
    • المصدر:
      Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : Nature Publishing Group, copyright 2011-
    • الموضوع:
    • نبذة مختصرة :
      Female and latent genital tuberculosis (FGTB and LGTB) in young women may lead to infertility by damaging ovarian reserve function, but the regulatory mechanisms remain unclear. In this study, we investigated the effects of FGTB and LGTB on ovarian reserve function and potential regulatory mechanisms by untargeted metabolomics of follicular fluid, aiming to provide insights for the clinical management and treatment approaches for afflicted women. We recruited 19 patients with FGTB, 16 patients with LGTB, and 16 healthy women as a control group. Clinical data analysis revealed that both the FGTB and LGTB groups had significantly lower ovarian reserve marker levels compared to the control group, including lower anti-Müllerian hormone levels (FGTB: 0.82 [0.6, 1.1] μg/L; LGTB: 1.57 [1.3, 1.8] μg/L vs. control: 3.29 [2.9, 3.5] μg/L), reduced antral follicular counts (FGTB: 6 [5.5, 9.5]; LGTB: 10.5 [7, 12.3] vs. control: 17 [14.5, 18]), and fewer retrieved oocytes (FGTB: 3 [2, 5]; LGTB: 8 [4, 8.3] vs. control: 14.5 [11.5, 15.3]). Conversely, these groups exhibited higher ovarian response marker levels, such as longer gonadotropin treatment days (FGTB: 12 [10.5, 12.5]; LGTB: 11 [10.8, 11.3] vs. control: 10 [8.8, 10]) and increased gonadotropin dosage requirements (FGTB: 3300 [3075, 3637.5] U; LGTB: 3037.5 [2700, 3225] U vs. control: 2531.25 [2337.5, 2943.8] U). All comparisons were statistically significant at P < 0.05. The results suggested that FGTB and LGTB have adverse effects on ovarian reserve and response. Untargeted metabolomic analysis identified 92 and 80 differential metabolites in the control vs. FGTB and control vs. LGTB groups, respectively. Pathway enrichment analysis revealed significant alterations in metabolic pathways in the FGTB and LGTB groups compared to the control group (P < 0.05), with specific changes noted in galactose metabolism, biotin metabolism, steroid hormone biosynthesis, and nicotinate and nicotinamide metabolism in the FGTB group, and caffeine metabolism, primary bile acid biosynthesis, steroid hormone biosynthesis, and glycerophospholipid metabolism in the LGTB group. The analysis of metabolic levels has revealed the potential mechanisms by which FGTB and LGTB affect ovarian reserve function, namely through alterations in metabolic pathways. The study emphasizes the importance of comprehending the metabolic alterations associated with FGTB and LGTB, which is of considerable relevance for the clinical management and therapeutic approaches in afflicted women.
      (© 2024. The Author(s).)
    • References:
      Int J Reprod Biomed. 2017 Jul;15(7):391-402. (PMID: 29177241)
      PLoS Med. 2016 Oct 25;13(10):e1002152. (PMID: 27780211)
      Int J Mycobacteriol. 2021 Jan-Mar;10(1):66-70. (PMID: 33707374)
      Indian J Urol. 2008 Jul;24(3):356-61. (PMID: 19468469)
      Open Forum Infect Dis. 2022 Oct 21;9(11):ofac543. (PMID: 36447614)
      Gynecol Endocrinol. 2020 Sep;36(9):819-823. (PMID: 31847626)
      J Reprod Dev. 2019 Feb 8;65(1):47-55. (PMID: 30449821)
      Lancet Microbe. 2023 Jan;4(1):e20. (PMID: 36521512)
      Med Sci Sports Exerc. 2001 Jan;33(1):9-14. (PMID: 11194117)
      Int J Gynaecol Obstet. 2002 Feb;76(2):159-63. (PMID: 11818110)
      Diagnostics (Basel). 2022 Feb 14;12(2):. (PMID: 35204580)
      Trop Med Infect Dis. 2022 Mar 08;7(3):. (PMID: 35324595)
      Am J Reprod Immunol. 2023 Feb;89(2):e13632. (PMID: 36494901)
      Mymensingh Med J. 2015 Jan;24(1):215-20. (PMID: 25725695)
      J Assist Reprod Genet. 1998 Jul;15(6):378-80. (PMID: 9673882)
      Fertil Steril. 1989 Mar;51(3):538-41. (PMID: 2920855)
      J Immunol. 2017 Feb 1;198(3):999-1005. (PMID: 28115589)
      Int J Reprod Biomed. 2019 Dec 30;17(12):929-934. (PMID: 32095740)
      JAMA. 2017 Oct 10;318(14):1367-1376. (PMID: 29049585)
      Hum Reprod. 2017 Nov 1;32(11):2269-2278. (PMID: 29040513)
      PLoS One. 2009 Oct 06;4(10):e7333. (PMID: 19806215)
      Infect Dis Obstet Gynecol. 2022 Nov 18;2022:3548190. (PMID: 36438172)
      Biogerontology. 2019 Dec;20(6):763-782. (PMID: 31538262)
      Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):1937-49. (PMID: 24894340)
      Clin Infect Dis. 2015 Oct 15;61Suppl 3:S102-18. (PMID: 26409271)
      Med Sci Monit. 2018 May 21;24:3357-3365. (PMID: 29783268)
      Sci China Life Sci. 2022 Aug;65(8):1563-1577. (PMID: 35167018)
      J Steroid Biochem Mol Biol. 2019 Jan;185:142-149. (PMID: 30121347)
      Fertil Steril. 1988 May;49(5):848-53. (PMID: 3360173)
      Hum Reprod. 2018 Jul 1;33(7):1262-1269. (PMID: 29897442)
      Steroids. 2013 Aug;78(8):777-81. (PMID: 23624033)
      J Ovarian Res. 2021 Aug 6;14(1):102. (PMID: 34362406)
      J Hum Reprod Sci. 2023 Apr-Jun;16(2):125-131. (PMID: 37547096)
      Lancet Public Health. 2023 Apr;8(4):e305-e310. (PMID: 36780916)
      J Pak Med Assoc. 2006 Jul;56(7):306-9. (PMID: 16900710)
      Indian J Med Res. 2017 Apr;145(4):425-436. (PMID: 28862174)
      Fertil Steril. 2010 Feb;93(3):681-90. (PMID: 19939362)
      Int J Tuberc Lung Dis. 2006 Sep;10(9):1045-50. (PMID: 16964799)
      Indian J Tuberc. 2020 Jul;67(3):295-311. (PMID: 32825856)
      Metabolites. 2021 Dec 06;11(12):. (PMID: 34940603)
      Expert Rev Mol Diagn. 2022 Jun;22(6):625-642. (PMID: 34882522)
      J Obstet Gynaecol India. 2015 Dec;65(6):362-71. (PMID: 26663993)
      Front Endocrinol (Lausanne). 2022 Nov 15;13:1030201. (PMID: 36457552)
      Public Health. 2017 Jul;148:56-62. (PMID: 28404534)
      Curr Opin Obstet Gynecol. 2023 Jun 1;35(3):263-269. (PMID: 36912346)
      Fertil Steril. 2012 May;97(5):1078-84.e1-8. (PMID: 22365382)
    • Grant Information:
      2022YFSH0067 Inner Mongolia Autonomous Region Science and Technology Plan Project; 2021GG0389 Inner Mongolia Autonomous Region Science and Technology Plan Project; YKD2024QN004 Inner Mongolia Medical University Youth Project; EP2100003598 Talent Introduction Project of the Inner Mongolia Autonomous Region
    • Contributed Indexing:
      Keywords: Female genital tuberculosis; Latent genital tuberculosis; Ovarian reserve function; Ovarian response; Untargeted metabolomics
    • الرقم المعرف:
      80497-65-0 (Anti-Mullerian Hormone)
      0 (Biomarkers)
    • الموضوع:
      Date Created: 20240425 Date Completed: 20240425 Latest Revision: 20240428
    • الموضوع:
      20240428
    • الرقم المعرف:
      PMC11045857
    • الرقم المعرف:
      10.1038/s41598-024-60167-7
    • الرقم المعرف:
      38664479